Cara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program

MT Newswires Live06-19

Cara Therapeutics (CARA) late Tuesday disclosed plans to explore strategic alternatives and lay off 70% workforce after discontinuing work on its difelikefalin drug candidate last week for failing to show clinical benefit in pruritus treatment, a nerve disorder.

The company is expecting to recognize around $2.6 million in one-time charges associated with the job cuts, mostly for termination costs during the current and upcoming quarters this year. The company expects to complete the workforce reduction by the end of June.

Cara said previously that it had about $70 million in cash, equivalents and marketable securities on hand at the end of March.

Cara shares were up more than 3% in extended trading, after a nearly 5% regular-session decline.

Price: 0.2502, Change: +0.01, Percent Change: +3.13

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444657894?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-19 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444657894","market":"sh","top_or_hot":-1,"title":"Cara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program","media":"MT Newswires Live","content":"<html><body><p> Cara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CARA) late Tuesday disclosed plans to explore strategic alternatives and lay off 70% workforce after discontinuing work on its difelikefalin drug candidate last week for failing to show clinical benefit in pruritus treatment, a nerve disorder.</p><p>The company is expecting to recognize around $2.6 million in one-time charges associated with the job cuts, mostly for termination costs during the current and upcoming quarters this year. The company expects to complete the workforce reduction by the end of June.</p><p>Cara said previously that it had about $70 million in cash, equivalents and marketable securities on hand at the end of March.</p><p>Cara shares were up more than 3% in extended trading, after a nearly 5% regular-session decline.</p><p>Price: 0.2502, Change: +0.01, Percent Change: +3.13</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-19 05:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cara Therapeutics (CARA) late Tuesday disclosed plans to explore strategic alternatives and lay off 70% workforce after discontinuing work on its difelikefalin drug candidate last week for failing to ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2444657894","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444657894","pubTimestamp":1718745079,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cara Therapeutics  late Tuesday disclosed plans to explore strategic alternatives and lay off 70% workforce after discontinuing work on its difelikefalin drug candidate last week for failing to show clinical benefit in pruritus treatment, a nerve disorder.The company is expecting to recognize around $2.6 million in one-time charges associated with the job cuts, mostly for termination costs during the current and upcoming quarters this year. The company expects to complete the workforce reduction by the end of June.Cara said previously that it had about $70 million in cash, equivalents and marketable securities on hand at the end of March.Cara shares were up more than 3% in extended trading, after a nearly 5% regular-session decline.Price: 0.2502, Change: +0.01, Percent Change: +3.13","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CARA":"Cara Therapeutics, Inc."},"translate_title":"Cara Therapeutics将闲置70%的员工，在取消Notalgia Paresthetica计划后探索替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CARA":1},"content_text":"Cara Therapeutics (CARA) late Tuesday disclosed plans to explore strategic alternatives and lay off 70% workforce after discontinuing work on its difelikefalin drug candidate last week for failing to show clinical benefit in pruritus treatment, a nerve disorder.The company is expecting to recognize around $2.6 million in one-time charges associated with the job cuts, mostly for termination costs during the current and upcoming quarters this year. The company expects to complete the workforce reduction by the end of June.Cara said previously that it had about $70 million in cash, equivalents and marketable securities on hand at the end of March.Cara shares were up more than 3% in extended trading, after a nearly 5% regular-session decline.Price: 0.2502, Change: +0.01, Percent Change: +3.13","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444657894"}